vimarsana.com

Page 70 - Unity Lab Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Thermo Fisher Scientific to Host the Science for Sustainability Symposia, in April 2021

Thermo Fisher Scientific Announces New System for Flexible, Automated Sample Purification

Thermo Fisher Scientific Announces New System for Flexible, Automated Sample Purification KingFisher Apex Purification System isolates nucleic acids, proteins and cells with customizable protocols News provided by Share this article Share this article CARLSBAD, Calif., April 1, 2021 /PRNewswire/  Thermo Fisher Scientific today launched the Thermo Scientific KingFisher Apex Purification System, a high-throughput sample purification instrument designed for scientists who need to automate the extraction of DNA, RNA, proteins and cells from an array of sample types. The instrument is easy to use, saves time and enables consistent results even as laboratory needs evolve.   The KingFisher Apex enables nucleic acid, protein and cell isolation while allowing users to customize protocols directly from the instrument to provide flexible, reproducible and fast sample preparation without additional expense or complexity. It automates much of the error-prone work associated with preparin

Thermo Fisher Scientific Investments Support Rapidly Increasing Bioprocessing Production

Thermo Fisher Scientific Investments Support Rapidly Increasing Bioprocessing Production Thermo Fisher Scientific Inc. the world leader in serving science, today announced more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022. These investments are expected to more than double the company’s current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term … Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022. These investments are expected to more than double the company’s current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.